Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients
Heart failure (HF) poses significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor reflective of the overall cardiovascular performance index in HF. We aimed to determine the effectiveness of force-titration of vals...
Gespeichert in:
| Veröffentlicht in: | Yonsei medical journal 2021, 62(5), , pp.391-399 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 399 |
|---|---|
| container_issue | 5 |
| container_start_page | 391 |
| container_title | Yonsei medical journal |
| container_volume | 62 |
| creator | Ahn, Kyung Jin Yu, Jongwook Jang, Albert Youngwoo Kim, Dae Hyeok Kwan, Jun Chung, Wook Jin |
| description | Heart failure (HF) poses significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor reflective of the overall cardiovascular performance index in HF. We aimed to determine the effectiveness of force-titration of valsartan on VVI values in HF patients.
In this multicenter and prospective observational trial, the effect of valsartan was stratified according to dosages [non-ceiling dose (NCD) vs. ceiling dose (CD)] in HF patients with left ventricular ejection fraction (LVEF) |
| doi_str_mv | 10.3349/ymj.2021.62.5.391 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_9776267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33908209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-6def091a0baf4021f1098ecd9f8a48a3d49cbd7c534fe64cd5d2f5aafa740e893</originalsourceid><addsrcrecordid>eNpVkUtrGzEUhUVpaNy0P6CboG0XM9Vr9NgEgt0khkBCcL1VrzWSq2SsMRo71P8-st2GZHW43HO-y-Ug9I2SmnNhfuxWjzUjjNaS1U3NDf2ARtQoWTHB1Uc0Ig3lVaOMPEWfh-GREKYoYZ_QKeeGaEbMCP2eQzdA3kDCk36Apcd9wnOfNjm6bddXcxiKQsbjfrvuYlriaWr9373ZVxO_9mVKbodjwje-cPAVxG6bPb6HTSyY4Qs6CeWE__pPz9Cvq5-z8U11e3c9HV_eVo7rZlPJ1gdiKJAFBFFeCpQY7V1rggahgbfCuEWrXMNF8FK4tmlZaAACKEG8NvwMfT9yUw72yUXbQzzosrdP2V4-zKbWKCWZVMV7cfSut4uVb93-XejsOscV5N0h-X6T4p_CebaaaCGNLgB6BLjcD0P24TVLid1XY0s1dl-Nlcw2tlRTMudvj74m_nfBXwBk3Y2d</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients</title><source>KoreaMed Synapse</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>KoreaMed Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ahn, Kyung Jin ; Yu, Jongwook ; Jang, Albert Youngwoo ; Kim, Dae Hyeok ; Kwan, Jun ; Chung, Wook Jin</creator><creatorcontrib>Ahn, Kyung Jin ; Yu, Jongwook ; Jang, Albert Youngwoo ; Kim, Dae Hyeok ; Kwan, Jun ; Chung, Wook Jin</creatorcontrib><description>Heart failure (HF) poses significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor reflective of the overall cardiovascular performance index in HF. We aimed to determine the effectiveness of force-titration of valsartan on VVI values in HF patients.
In this multicenter and prospective observational trial, the effect of valsartan was stratified according to dosages [non-ceiling dose (NCD) vs. ceiling dose (CD)] in HF patients with left ventricular ejection fraction (LVEF) <55%. Biochemical studies, including N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography with VVI, the treadmill test, and the activity scale index were assessed at baseline and after 24 weeks of treatment.
One-hundred thirty-eight patients were force-titrated to either a CD group (n=81) or a NCD group (n=57). The mean age of the study participants was 59 years and 66% were male. After 6 months of follow up, left ventricular mass index (LVMI) values had significantly improved in the CD group but not in the NCD group. Intriguingly, in HF patients with a reduced ejection fraction (HFrEF) (n=52, LVEF <40%), a significant improvement in VVI was only observed in the CD group (from 2.4±0.6 to 1.8±0.5,
<0.001).
CDs of valsartan for 6 months showed better improvement in VVI, as well as LVMI, in patients with HFrEF, compared with NCDs.</description><identifier>ISSN: 0513-5796</identifier><identifier>EISSN: 1976-2437</identifier><identifier>DOI: 10.3349/ymj.2021.62.5.391</identifier><identifier>PMID: 33908209</identifier><language>eng</language><publisher>Korea (South): Yonsei University College of Medicine</publisher><subject>Aminobutyrates ; Drug Combinations ; Female ; Heart Failure - drug therapy ; Humans ; Male ; Middle Aged ; Natriuretic Peptide, Brain ; Original ; Peptide Fragments ; Stroke Volume ; Tetrazoles ; Valsartan - therapeutic use ; Ventricular Function, Left ; 의학일반</subject><ispartof>Yonsei Medical Journal, 2021, 62(5), , pp.391-399</ispartof><rights>Copyright: Yonsei University College of Medicine 2021.</rights><rights>Copyright: Yonsei University College of Medicine 2021 2021 Yonsei University College of Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c385t-6def091a0baf4021f1098ecd9f8a48a3d49cbd7c534fe64cd5d2f5aafa740e893</cites><orcidid>0000-0001-8308-7866 ; 0000-0002-9767-7098 ; 0000-0001-7489-2222 ; 0000-0003-2513-0920 ; 0000-0002-8802-268X ; 0000-0002-6286-3157</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084698/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084698/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33908209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002707908$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Ahn, Kyung Jin</creatorcontrib><creatorcontrib>Yu, Jongwook</creatorcontrib><creatorcontrib>Jang, Albert Youngwoo</creatorcontrib><creatorcontrib>Kim, Dae Hyeok</creatorcontrib><creatorcontrib>Kwan, Jun</creatorcontrib><creatorcontrib>Chung, Wook Jin</creatorcontrib><title>Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients</title><title>Yonsei medical journal</title><addtitle>Yonsei Med J</addtitle><description>Heart failure (HF) poses significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor reflective of the overall cardiovascular performance index in HF. We aimed to determine the effectiveness of force-titration of valsartan on VVI values in HF patients.
In this multicenter and prospective observational trial, the effect of valsartan was stratified according to dosages [non-ceiling dose (NCD) vs. ceiling dose (CD)] in HF patients with left ventricular ejection fraction (LVEF) <55%. Biochemical studies, including N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography with VVI, the treadmill test, and the activity scale index were assessed at baseline and after 24 weeks of treatment.
One-hundred thirty-eight patients were force-titrated to either a CD group (n=81) or a NCD group (n=57). The mean age of the study participants was 59 years and 66% were male. After 6 months of follow up, left ventricular mass index (LVMI) values had significantly improved in the CD group but not in the NCD group. Intriguingly, in HF patients with a reduced ejection fraction (HFrEF) (n=52, LVEF <40%), a significant improvement in VVI was only observed in the CD group (from 2.4±0.6 to 1.8±0.5,
<0.001).
CDs of valsartan for 6 months showed better improvement in VVI, as well as LVMI, in patients with HFrEF, compared with NCDs.</description><subject>Aminobutyrates</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Natriuretic Peptide, Brain</subject><subject>Original</subject><subject>Peptide Fragments</subject><subject>Stroke Volume</subject><subject>Tetrazoles</subject><subject>Valsartan - therapeutic use</subject><subject>Ventricular Function, Left</subject><subject>의학일반</subject><issn>0513-5796</issn><issn>1976-2437</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUtrGzEUhUVpaNy0P6CboG0XM9Vr9NgEgt0khkBCcL1VrzWSq2SsMRo71P8-st2GZHW43HO-y-Ug9I2SmnNhfuxWjzUjjNaS1U3NDf2ARtQoWTHB1Uc0Ig3lVaOMPEWfh-GREKYoYZ_QKeeGaEbMCP2eQzdA3kDCk36Apcd9wnOfNjm6bddXcxiKQsbjfrvuYlriaWr9373ZVxO_9mVKbodjwje-cPAVxG6bPb6HTSyY4Qs6CeWE__pPz9Cvq5-z8U11e3c9HV_eVo7rZlPJ1gdiKJAFBFFeCpQY7V1rggahgbfCuEWrXMNF8FK4tmlZaAACKEG8NvwMfT9yUw72yUXbQzzosrdP2V4-zKbWKCWZVMV7cfSut4uVb93-XejsOscV5N0h-X6T4p_CebaaaCGNLgB6BLjcD0P24TVLid1XY0s1dl-Nlcw2tlRTMudvj74m_nfBXwBk3Y2d</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Ahn, Kyung Jin</creator><creator>Yu, Jongwook</creator><creator>Jang, Albert Youngwoo</creator><creator>Kim, Dae Hyeok</creator><creator>Kwan, Jun</creator><creator>Chung, Wook Jin</creator><general>Yonsei University College of Medicine</general><general>연세대학교의과대학</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0001-8308-7866</orcidid><orcidid>https://orcid.org/0000-0002-9767-7098</orcidid><orcidid>https://orcid.org/0000-0001-7489-2222</orcidid><orcidid>https://orcid.org/0000-0003-2513-0920</orcidid><orcidid>https://orcid.org/0000-0002-8802-268X</orcidid><orcidid>https://orcid.org/0000-0002-6286-3157</orcidid></search><sort><creationdate>20210501</creationdate><title>Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients</title><author>Ahn, Kyung Jin ; Yu, Jongwook ; Jang, Albert Youngwoo ; Kim, Dae Hyeok ; Kwan, Jun ; Chung, Wook Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-6def091a0baf4021f1098ecd9f8a48a3d49cbd7c534fe64cd5d2f5aafa740e893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aminobutyrates</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Natriuretic Peptide, Brain</topic><topic>Original</topic><topic>Peptide Fragments</topic><topic>Stroke Volume</topic><topic>Tetrazoles</topic><topic>Valsartan - therapeutic use</topic><topic>Ventricular Function, Left</topic><topic>의학일반</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ahn, Kyung Jin</creatorcontrib><creatorcontrib>Yu, Jongwook</creatorcontrib><creatorcontrib>Jang, Albert Youngwoo</creatorcontrib><creatorcontrib>Kim, Dae Hyeok</creatorcontrib><creatorcontrib>Kwan, Jun</creatorcontrib><creatorcontrib>Chung, Wook Jin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Yonsei medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ahn, Kyung Jin</au><au>Yu, Jongwook</au><au>Jang, Albert Youngwoo</au><au>Kim, Dae Hyeok</au><au>Kwan, Jun</au><au>Chung, Wook Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients</atitle><jtitle>Yonsei medical journal</jtitle><addtitle>Yonsei Med J</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>62</volume><issue>5</issue><spage>391</spage><epage>399</epage><pages>391-399</pages><issn>0513-5796</issn><eissn>1976-2437</eissn><abstract>Heart failure (HF) poses significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor reflective of the overall cardiovascular performance index in HF. We aimed to determine the effectiveness of force-titration of valsartan on VVI values in HF patients.
In this multicenter and prospective observational trial, the effect of valsartan was stratified according to dosages [non-ceiling dose (NCD) vs. ceiling dose (CD)] in HF patients with left ventricular ejection fraction (LVEF) <55%. Biochemical studies, including N-terminal pro-B-type natriuretic peptide (NT-proBNP), echocardiography with VVI, the treadmill test, and the activity scale index were assessed at baseline and after 24 weeks of treatment.
One-hundred thirty-eight patients were force-titrated to either a CD group (n=81) or a NCD group (n=57). The mean age of the study participants was 59 years and 66% were male. After 6 months of follow up, left ventricular mass index (LVMI) values had significantly improved in the CD group but not in the NCD group. Intriguingly, in HF patients with a reduced ejection fraction (HFrEF) (n=52, LVEF <40%), a significant improvement in VVI was only observed in the CD group (from 2.4±0.6 to 1.8±0.5,
<0.001).
CDs of valsartan for 6 months showed better improvement in VVI, as well as LVMI, in patients with HFrEF, compared with NCDs.</abstract><cop>Korea (South)</cop><pub>Yonsei University College of Medicine</pub><pmid>33908209</pmid><doi>10.3349/ymj.2021.62.5.391</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-8308-7866</orcidid><orcidid>https://orcid.org/0000-0002-9767-7098</orcidid><orcidid>https://orcid.org/0000-0001-7489-2222</orcidid><orcidid>https://orcid.org/0000-0003-2513-0920</orcidid><orcidid>https://orcid.org/0000-0002-8802-268X</orcidid><orcidid>https://orcid.org/0000-0002-6286-3157</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0513-5796 |
| ispartof | Yonsei Medical Journal, 2021, 62(5), , pp.391-399 |
| issn | 0513-5796 1976-2437 |
| language | eng |
| recordid | cdi_nrf_kci_oai_kci_go_kr_ARTI_9776267 |
| source | KoreaMed Synapse; MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; KoreaMed Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Aminobutyrates Drug Combinations Female Heart Failure - drug therapy Humans Male Middle Aged Natriuretic Peptide, Brain Original Peptide Fragments Stroke Volume Tetrazoles Valsartan - therapeutic use Ventricular Function, Left 의학일반 |
| title | Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T05%3A30%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Valsartan%20Dosage%20on%20Ventriculo-Vascular%20Coupling%20Index%20Dose-Dependency%20in%20Heart%20Failure%20Patients&rft.jtitle=Yonsei%20medical%20journal&rft.au=Ahn,%20Kyung%20Jin&rft.date=2021-05-01&rft.volume=62&rft.issue=5&rft.spage=391&rft.epage=399&rft.pages=391-399&rft.issn=0513-5796&rft.eissn=1976-2437&rft_id=info:doi/10.3349/ymj.2021.62.5.391&rft_dat=%3Cpubmed_nrf_k%3E33908209%3C/pubmed_nrf_k%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33908209&rfr_iscdi=true |